Candel Therapeutics, Inc.
CADL$288M
Micro CapNASDAQBiological Products, (No Diagnostic Substances)🇺🇸North AmericaNEEDHAM38 employees
Drugs in Pipeline
3
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Jun 15, 2026
14wMarket Overview
Stock performance and key metrics
CADL News
Catalyst Timeline
1 upcoming, 0 past
Drug Pipeline
Aglatimagene besadenovec + valacyclovir
Prostate Cancer
aglatimagene besadenovec
Prostate Cancer
CAN-2409
Malignant Glioma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Aglatimagene besadenovec + valacyclovir | Phase 3 | Prostate Cancer | - | - |
aglatimagene besadenovec | Phase 2 | Prostate Cancer | - | - |
CAN-2409 | Phase 2 | Malignant Glioma | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply